Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study

Russo, Vincenzo; Maio, Marco Di; Attena, Emilio; Silverio, Angelo; Scudiero, Fernando; Celentani, Dario; Lodigiani, Corrado; Micco, Pierpaolo Di

doi:10.1016/j.phrs.2020.104965

Cited by 103 publications

(140 citation statements)

References 9 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of PE in COVID-19 patients ranges from 15% to 40%; this large difference across clinical studies may be due tothe size and heterogeneity of sample populations, presenting significant differences in clinical characteristics, pre-admission pharmacological treatments and anticoagulation regimens used for VTE prophylaxis during the hospitalization [ 14 , 15 , 16 , 17 ]. Moreover, the timing and the methodology to perform VTE diagnosis are heterogeneous across different studies [ 18 , 19 , 20 ]. Similar counteracting data may be found for the clinical indication to perform thromboprophylaxis with low molecular weight heparin after discharge.…”

mentioning

confidence: 99%

Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate

2020

Self Cite

View full text Add to dashboard Cite

Asreported by the World Health Organization, a novel coronavirus (COVID-19) was identified as the causative virus of new viral pneumonia of unknown etiology by Chinese authorities on 7 January 2020. The virus was named COVID-19 and because of its ability to cause severe acute respiratory syndrome (i.e., SARS) this infection has also been defined as SARS-CoV2.Furthermore, an association between COVID-19 infection and venous thromboembolism has been reported in several series around the world.For this reason, methods used to improve diagnostic tools, pharmacological thromboprophylaxis and type of anticoagulants are discussed in this expert opinion.

show abstract

mentioning

confidence: 99%

Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate

2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast to these early experiences, the two largest observational studies, including 1099 Chinese and 5700 U.S. COVID-19 patients respectively, did not report any arrhythmias [21,28]. A recent Italian multicenter observational study showed a prevalence of 12.5% among hospitalized COVID-19 patients [29]; moreover, a report by the COVID-19 Task Force of the Italian National Institute of Health showed that 22.5% of non-surviving COVID-19 patients (n: 355, mean age 79.5 years, 30% women) presented atrial fibrillation as comorbidity diagnosed before the SARS-CoV-2 infection [50]. The approach to atrial fibrillation (AF) management should take into consideration several pharmacological interactions between antiarrhythmic and experimental COVID-19 therapies [51] Ventricular arrhythmias seem to be directly correlated to COVID-19 induced myocardial injury Among a cohort of 187 COVID-19 patients without history of arrhythmias, the subjects with elevated TnT levels more frequently developed malignant arrhythmias, including ventricular tachycardia and fibrillation during hospitalization (2 (1.5%) vs. 9 (17.3%) compared to those with normal TnT levels [52].…”

Section: Arrhythmiasmentioning

confidence: 86%

COVID-19 and Heart: From Clinical Features to Pharmacological Implications

Russo

Bottino

Carbone

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

A highly pathogenic human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized in Wuhan, China, as the cause of the coronavirus disease 2019 (COVID-19) outbreak which has spread rapidly from China to other countries in the world, causing a pandemic with alarming morbidity and mortality. The emerging epidemiological data about COVID-19 patients suggest an association between cardiovascular diseases (CVD) and SARS-CoV-2 infection, in term of clinical features at hospital admission and prognosis for disease severity. The aim of our review is to describe the cardiological features of COVID-19 patients at admission, the acute cardiac presentation, the clinical outcome for patients with underlying CVD and the pharmacological implications for disease management.

show abstract

“…To avoid thrombotic complications, many have recommended prophylactic antithrombotic pharmacological therapies for COVID-19 patients, along with particular dosing instructions (34)(35)(36)(37). However, to date, little research has been conducted and the optimal doses of anticoagulants or antiplatelet agents has yet to be determined.…”

Section: Mitigation Of Covid-19 Thrombotic Complicationsmentioning

confidence: 99%

Thrombosis and COVID-19: The Potential Role of Nutrition

2020

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the coronavirus disease (COVID-19), is a contagion that has rapidly spread around the globe. COVID-19 has caused significant loss of life and disrupted global society at a level never before encountered. While the disease was predominantly characterized by respiratory symptoms initially, it became clear that other systems including the cardiovascular and neurological systems were also involved. Several thrombotic complications were reported including venous thrombosis, vasculitis, cardiomyopathy, and stroke. Thrombosis and inflammation are implicated in various non-communicable diseases (NCDs). This is of significant concern as people with pre-existing conditions such as cardiovascular disorders, renal disorders, obesity, metabolic syndrome, and diabetes are at greater risk of severe COVID-19 infection. Consequently, the research surrounding the use of anticoagulants, antiplatelet, and antithrombotic strategies for prophylaxis and treatment of COVID-19 is of critical importance. The adoption of a healthy diet, physical exercise, and lifestyle choices can reduce the risk factors associated with NCDs and the thrombo-inflammatory complications. In this review, these thrombotic complications and potential foods, nutraceuticals, and the antithrombotic constituents within that may prevent the onset of severe thrombotic complications as a result of infection are discussed. While nutrition is not a panacea to tackle COVID-19, it is apparent that a patient's nutritional status may affect patient outcomes. Further intensive research is warranted to reduce to incidence of thrombotic complications.

show abstract

Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study

Cited by 103 publications

References 9 publications

Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate

Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate

COVID-19 and Heart: From Clinical Features to Pharmacological Implications

Thrombosis and COVID-19: The Potential Role of Nutrition

Contact Info

Product

Resources

About